IDEXX Laboratories, Inc. (NASDAQ:IDXX) Shares Sold by Oarsman Capital Inc.

Oarsman Capital Inc. trimmed its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 8.8% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 446 shares of the company’s stock after selling 43 shares during the period. Oarsman Capital Inc.’s holdings in IDEXX Laboratories were worth $184,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also recently modified their holdings of the business. Rialto Wealth Management LLC acquired a new stake in IDEXX Laboratories in the 4th quarter valued at about $30,000. Retirement Wealth Solutions LLC purchased a new stake in shares of IDEXX Laboratories in the fourth quarter valued at approximately $31,000. Kestra Investment Management LLC acquired a new stake in shares of IDEXX Laboratories in the fourth quarter valued at approximately $38,000. Crews Bank & Trust purchased a new position in IDEXX Laboratories during the fourth quarter worth approximately $41,000. Finally, BankPlus Trust Department acquired a new position in IDEXX Laboratories during the fourth quarter worth $60,000. 87.84% of the stock is owned by hedge funds and other institutional investors.

IDEXX Laboratories Price Performance

IDXX opened at $393.73 on Friday. The firm has a market cap of $31.91 billion, a price-to-earnings ratio of 36.90, a PEG ratio of 3.41 and a beta of 1.39. The company has a current ratio of 1.31, a quick ratio of 0.95 and a debt-to-equity ratio of 0.28. The stock’s 50-day moving average price is $435.55 and its 200 day moving average price is $439.81. IDEXX Laboratories, Inc. has a 12-month low of $393.50 and a 12-month high of $548.88.

Analyst Upgrades and Downgrades

A number of equities research analysts recently issued reports on the stock. Morgan Stanley dropped their price objective on shares of IDEXX Laboratories from $559.00 to $550.00 and set an “overweight” rating for the company in a report on Wednesday, January 29th. Bank of America raised their price target on shares of IDEXX Laboratories from $475.00 to $535.00 and gave the stock a “neutral” rating in a report on Tuesday, February 4th. Piper Sandler increased their price objective on IDEXX Laboratories from $435.00 to $510.00 and gave the stock a “neutral” rating in a research report on Monday, February 10th. Barclays raised their target price on IDEXX Laboratories from $481.00 to $520.00 and gave the stock an “overweight” rating in a research note on Tuesday, February 4th. Finally, StockNews.com raised IDEXX Laboratories from a “hold” rating to a “buy” rating in a research report on Friday. Three analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $533.75.

Insider Transactions at IDEXX Laboratories

In other IDEXX Laboratories news, EVP George Fennell sold 9,986 shares of the firm’s stock in a transaction that occurred on Monday, February 10th. The shares were sold at an average price of $462.53, for a total value of $4,618,824.58. Following the completion of the transaction, the executive vice president now owns 8,176 shares of the company’s stock, valued at $3,781,645.28. This trade represents a 54.98 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Also, Director M Anne Szostak sold 3,000 shares of the business’s stock in a transaction on Friday, February 7th. The stock was sold at an average price of $465.94, for a total transaction of $1,397,820.00. Following the completion of the transaction, the director now owns 3,061 shares of the company’s stock, valued at approximately $1,426,242.34. This trade represents a 49.50 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 2.11% of the company’s stock.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.